Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 15 of 5804
-
Can a new daily pill quiet the immune attack behind psoriasis?
Disease control Not yet recruitingThis study is a multicenter, randomized, double-blind, placebo- and active-controlled Phase III clinical trial sponsored by Nanjing Shunxin Pharmaceutical Co., Ltd., a subsidiary of Chiatai Tianqing Pharmaceutical Group. The study aims to evaluate the efficacy and safety of once-…
Phase: PHASE3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Dual-Action antibody may boost chemoradiotherapy against High-Risk nasopharyngeal cancer
Disease control Not yet recruitingThis trial aims to study the role of Ivonescimab combined with chemoradiotherapy in high-Risk locoregionally advanced nasopharyngeal carcinoma.
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug combo aims to outperform immunotherapy in Hard-to-Treat stomach cancer
Disease control Not yet recruitingThis study is a randomized, open, multicenter phase III clinical study designed to compare the efficacy and safety of QLS31905 injection combined with CAPOX versus sintilimab combined with CAPOX in the first-line treatment of CLDN18.2 positive, PD-L1 CPS \< 5 unresectable locally…
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Can a burst of radiation make CAR t-cells fight cancer harder?
Disease control Not yet recruitingThis is a clinical trial to evaluate the safety of combining CAR T-cell therapy with low-dose total body irradiation (LD-TBI) in patients with previously treated large B-cell lymphoma (LBCL) or multiple myeloma (MM). The investigators' hypothesis is that the combination will make…
Phase: PHASE1 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Could a common supplement protect the failing heart? a major trial puts Alpha-Lipoic acid to the test
Disease control Not yet recruitingChronic heart failure is a clinical condition caused by structural heart disease and is characterized by reduced pumping function, fluid retention, and abnormal activation of neurohormonal systems. It represents the advanced stage of many cardiovascular diseases and remains a maj…
Phase: PHASE3 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Could a cheap blood thinner cut stroke risk in africa?
Prevention Not yet recruitingGlobal estimates suggest that sub-Saharan Africa (SSA) now has the highest incidence, prevalence, and worst survival outcomes of stroke. With an estimated 1.4 million stroke survivors, outcomes of stroke in SSA are abysmal with 1-month case fatality at 30% and 3-year mortality ra…
Phase: PHASE3 • Sponsor: Northern California Institute of Research and Education • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
New hope for stroke patients: drug may work up to 24 hours later
Disease control Recruiting nowThe PEARL-SIMPLIFIED trial is a multicenter, prospective, randomized controlled, open-label, blinded-endpoint study. It aims to evaluate the efficacy and safety of intravenous tenecteplase (TNK) in patients with acute ischemic stroke (AIS) presenting in the extended 4.5-24 hour w…
Phase: PHASE3 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
AI could shorten the long road to a rare disease diagnosis
Diagnosis Not yet recruitingA multicentre randomised controlled trial evaluating whether a rare-disease diagnostic large language model can improve diagnostic quality, efficiency, and health-economic outcomes for physicians managing patients with suspected rare or diagnostically unresolved disease.
Phase: NA • Sponsor: Peking Union Medical College Hospital • Aim: Diagnosis
Last updated Jul 25, 2026 00:00 UTC
-
Precision radiation may boost hormone therapy for advanced prostate cancer
Disease control Not yet recruitingThis is a multicenter, randomized, open-label phase 2 study for men with metastatic hormone-sensitive prostate cancer. About 254 participants will first receive 6 months of darolutamide plus androgen deprivation therapy. Participants whose cancer has not progressed and who still …
Phase: PHASE2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Clot-Removal procedure may offer hope for severe brain stem strokes
Disease control Not yet recruitingAcute basilar artery occlusion is associated with high mortality and severe disability. Previous randomized trials have demonstrated the benefit of endovascular therapy in selected patients with basilar artery occlusion; however, patients with large ischemic core, commonly define…
Phase: NA • Sponsor: The First Affiliated Hospital of University of Science and Technology of China • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Heart pump may help High-Risk patients get Life-Saving artery treatment
Disease control Not yet recruitingBased on a multi-center randomized controlled study, this research aims to evaluate the efficacy and safety of interventional therapy supported by the CorVad percutaneous left ventricular assist system (Micro-axial Flow Pump) for patients with complex coronary heart disease (CHD)…
Phase: NA • Sponsor: China National Center for Cardiovascular Diseases • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Triple-Drug cocktail aims to tackle Hard-to-Treat cancers
Disease control Not yet recruitingThis study is designed to establish the safety of the combination of PD-1 inhibitor tislelizumab, an anti-angiogenic agent bevacizumab and a chemotherapeutic agent capecitabine, in a phase Ib setting and to evaluate preliminary efficacy in selected expansion cohorts, including PD…
Phase: PHASE1, PHASE2 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Spinal-Fluid vaccine targets breast cancer cells in the brain
Disease control Recruiting nowThe purpose of this study is to learn about the effects of the study treatment, Dendritic Cell Vaccine (DCV), in combination with trastuzumab or nivolumab to confirm the highest dose of the study treatment that can be given safely to participants with Breast Cancer (BC) with Lept…
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Single-session strategy could transform high-risk prostate cancer care
Disease control Not yet recruitingThis multicenter, prospective, single-arm study evaluates a novel streamlined pathway for men at high risk of clinically significant prostate cancer (csPCa) identified by the USTC model (probability ≥0.60). Under general anesthesia, participants undergo MRI/ultrasound fusion targ…
Phase: NA • Sponsor: Anhui Provincial Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Could fewer radiation sessions be just as effective for cervical cancer?
Disease control Not yet recruitingCervical cancer remains a major health problem in Thailand and other lowand middle-income countries. The current standard treatment for locally advanced cervical cancer consists of conventionally fractionated external beam radiotherapy delivered over 5-7 weeks with concurrent che…
Phase: PHASE3 • Sponsor: Mahidol University • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Hope for kids with tough cancer: new combo trial launches
Disease control Not yet recruitingPatients will then be randomized at study entry to one of three treatment arms. Patients on Arm A will receive a single treatment course with 131I-MIBG with vorinostat. Patients on Arm B will receive a single treatment course with 131I-MIBG and dinutuximab. Patients on Arm C will…
Phase: PHASE2 • Sponsor: New Approaches to Neuroblastoma Therapy Consortium • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Personalized TB treatment could shorten recovery time
⭐️ CURE ⭐️ Not yet recruitingThe A5414 study will evaluate whether treatment for drug-susceptible pulmonary tuberculosis (TB) can be tailored according to a participant's risk of an unfavorable outcome. Participants will be assigned to lower-risk or higher-risk groups using baseline characteristics and then …
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ CURE ⭐️
Last updated Jun 27, 2026 14:00 UTC
-
Combination therapy aims to outsmart tough lymphoma
Disease control Not yet recruitingThis phase II trial tests the effect of nemtabrutinib in combination with brexucabtagene autoleucel (brexu-cel) in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory).…
Phase: PHASE2 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New antibody drug aims to prevent strokes in irregular heartbeat
Disease control Not yet recruitingThis study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called apixaban. The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly. The aim of the…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Personalized mRNA vaccine aims to train immune system against ovarian cancer
Disease control Not yet recruitingThis is a Phase I, single-arm, open-label, dose-escalation study in patients with stage II or III ovarian cancer after surgery. The study will evaluate the safety, tolerability, immune response, and preliminary clinical activity of NeoOVIV, a personalized mRNA-lipid nanoparticle …
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC